SCHEMBL3916007

SCHEMBL3916007

CCOC(=O)CC(C)NC(=S)N1CCC2(CC1)NC(Cc1ccccc1)C(=O)N2C

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.39
HTT P42858 1/20 0.39
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 5/20 0.35
NPY2R P49146 1/20 0.35
LMNA P02545 2/20 0.35
POLB P06746 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
CYP2C9 P11712 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
SIGMAR1 Q99720 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3925378 0.83 KDM4E (0.32) HTTKDM4EALDH1A1KDM4C
SCHEMBL3917588 0.78 PLA2G10 (0.39) ALDH1A1POLBMEN1KMT2ACYP1A2
SCHEMBL1803909 0.74 PKM (0.53) PKMHTTKDM4EALDH1A1LMNA
SCHEMBL3928453 0.74 KDM4E (0.36) KDM4EALDH1A1NPY2RLMNAL3MBTL1
SCHEMBL3927372 0.74 MEN1 (0.46) HTTKDM4EALDH1A1LMNAPOLB
SCHEMBL4038265 0.73 KDM4E (0.37) KDM4ELMNAL3MBTL1MEN1KMT2A
SCHEMBL3917023 0.72 KDM4E (0.48) KDM4EALDH1A1LMNAMEN1KMT2A
SCHEMBL1802463 0.72 MEN1 (0.50) ALDH1A1LMNAPOLBL3MBTL1MEN1
SCHEMBL1801279 0.72 ALDH1A1 (0.39) ALDH1A1LMNAL3MBTL1MEN1KMT2A
SCHEMBL4041207 0.70 PLA2G10 (0.38) KDM4EALDH1A1LMNAPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7560468-B2 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2009-07-14 US claimed
EP-1730144-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5 DECAN-2-ONE COMPOUNDS GRUENENTHAL GMBH (DE) 2009-06-10 EP claimed
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US claimed
US-7560468-B2 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2009-07-14 US disclosed
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds THPO, UGT1A8, UGT1A4 PKM 1588/4885HTT 509/4885KDM4E 2581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.